REG - Genus - Appointment of Chief Financial Officer Designate

GenusAnnouncement

13/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250313:nRSM4584Aa&default-theme=true

RNS Number : 4584A  Genus PLC  13 March 2025

Genus plc

("Genus" or the "Company")

Appointment of Chief Financial Officer Designate

The Board of Genus (LSE: GNS), a leading global animal genetics company, is
pleased to announce that it has appointed Andy Russell as Chief Financial
Officer ("CFO") and Executive Director, following a comprehensive search
process.

Andy will commence with Genus and join the Board on 1(st) August 2025, taking
over from Alison Henriksen after she retires from the Company on 31(st) July
2025, after more than five years in the role.

Andy is an experienced CFO, who will join Genus after nearly 12 years with
global medical device manufacturer Smith & Nephew plc. He currently serves
as Senior Vice President, Group Finance and M&A, operating as deputy to
the Group CFO and leading approximately 400 people globally as he oversaw
Group reporting, Controllership, FP&A, Tax, Treasury and M&A. This
follows a succession of increasingly senior roles within the organisation,
including CFO for the Global Orthopedics division, Interim President for EMEA
and CFO for EMEA (while also acting as Finance lead for Global M&A and
Strategic Projects).

Before joining Smith & Nephew, Andy spent 17 years with KPMG, the last
three of them as a Director, Transaction Services in the National Markets
Division and the Private Equity Group.

Jorgen Kokke, Chief Executive Officer of Genus, said:

"I am delighted that we have been able to secure an executive of Andy's
caliber. His blend of deep finance expertise and strong commercial acumen will
help us take Genus through the next stage of its development as we continue to
pursue our strategic priorities".

Andy Russell, incoming CFO, said:

"I am excited to be joining a business that has so many growth opportunities
to execute against. I look forward to working with Jorgen and the Board to
capitalise on these prospects and deliver value to all our stakeholders".

 

For further information please contact:

Genus plc Tel: +44 125 634 5970

Jorgen Kokke, Chief Executive Officer

Alison Henriksen, Chief Financial Officer

Anand Date, Investor Relations & Sustainability Director

Burson Buchanan Tel: +44 207 466 5000

Charles Ryland; Toto Berger; Sophie Wills; Verity Parker

About Genus

Genus advances animal breeding and genetic improvement by applying
biotechnology and sells added value products for livestock farming and food
producers. Its technology is applicable across livestock species and is
currently commercialised by Genus in the dairy, beef and pork food production
sectors.

Genus's worldwide sales are made in over 85 countries under the trademarks
'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and
breeding animals with superior genetics to those animals currently in farms.
Genus's customers' animals produce offspring with greater production
efficiency and quality, and our customers use them to supply the global dairy
and meat supply chains.

Genus's competitive edge comes from the ownership and control of proprietary
lines of breeding animals, the biotechnology used to improve them and its
global supply chain, technical service and sales and distribution network. The
PRP is a market leading innovation in gene editing, which Genus is looking to
commercialise in the porcine industry once regulatory approval is gained.

Headquartered in Basingstoke, United Kingdom, Genus companies operate in over
24 countries on six continents, with research laboratories located in Madison,
Wisconsin, USA.

Remuneration

Andy Russell will receive a salary of £430,000.  He will receive a pension
contribution of 6% of salary as well as other standard core benefits.  Andy
will be eligible for discretionary variable remuneration. Under the current
Directors' Remuneration Policy the annual bonus maximum is 175% of salary and
there is potential to be awarded 200% of salary under the Company's
Performance Share Plan.

Further details including any buyout (if required) will be disclosed in full
in the Company's 2025 Directors' Remuneration Report.

 

Regulatory Notes This announcement is made in accordance with Listing Rule
6.4.6R.   There are no matters to be disclosed in connection with Listing
Rule 6.4.8R (1) - (6).

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.  The person responsible for making this announcement on behalf of the
Group is Vaughn Walton (Interim Group Company Secretary).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFSAVRIFLIE